###begin article-title 0
###xml 26 27 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 31 32 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 42 43 31 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 47 48 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor
###end article-title 0
###begin p 1
D.M. Beauvais and B.J. Ell contributed equally to this paper.
###end p 1
###begin p 2
###xml 101 102 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 106 107 99 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 117 118 106 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 122 123 108 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 493 494 475 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 498 499 477 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 509 510 484 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 514 515 486 487 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 275 280 <span type="species:ncbi:9606">human</span>
###xml 619 624 <span type="species:ncbi:9606">human</span>
###xml 879 884 <span type="species:ncbi:10090">mouse</span>
###xml 1002 1007 <span type="species:ncbi:10090">mouse</span>
###xml 1089 1094 <span type="species:ncbi:10090">mouse</span>
Syndecan-1 (Sdc1) is a matrix receptor shown to associate via its extracellular domain with the alphavbeta3 and alphavbeta5 integrins, potentially regulating cell adhesion, spreading, and invasion of cells expressing these integrins. Using Sdc1 deletion mutants expressed in human mammary carcinoma cells, we identified the active site within the Sdc1 core protein and derived a peptide inhibitor called synstatin (SSTN) that disrupts Sdc1's interaction with these integrins. Because the alphavbeta3 and alphavbeta5 integrins are critical in angiogenesis, a process in which a role for Sdc1 has been uncertain, we used human vascular endothelial cells in vitro to show that the Sdc1 regulatory mechanism is also required for integrin activation on these cells. We found Sdc1 expressed in the vascular endothelium during microvessel outgrowth from aortic explants in vitro and in mouse mammary tumors in vivo. Moreover, we show that SSTN blocks angiogenesis in vitro or when delivered systemically in a mouse model of angiogenesis in vivo, and impairs mammary tumor growth in an orthotopic mouse tumor model. Thus, Sdc1 is a critical regulator of these two important integrins during angiogenesis and tumorigenesis, and is inhibited by the novel SSTN peptide.
###end p 2
###begin p 3
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 353 354 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 376 377 372 373 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 381 382 374 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 392 393 381 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 397 398 383 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 432 433 414 415 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 437 438 416 417 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 448 449 423 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 453 454 425 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 580 581 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">3</xref>
Angiogenesis, or the sprouting of new blood vessels from existing ones, occurs during development and in diseases such as diabetic retinopathy, endometriosis, psoriasis, rheumatoid arthritis, and tumor-induced angiogenesis (1). Vascular endothelial cells rely on signaling from multiple integrins during the angiogenic process (for review see reference 2), including the alphavbeta3 and alphavbeta5 integrins; signaling by the alphavbeta3 and alphavbeta5 integrin leads to endothelial cell proliferation, migration, matrix metalloprotease activation, and resistance to apoptosis (3).
###end p 3
###begin p 4
###xml 9 10 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 14 15 7 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 25 26 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 30 31 16 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 345 346 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 479 480 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 615 616 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 617 618 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 909 911 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 954 956 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 1058 1060 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 1061 1063 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 1125 1127 1111 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
The alphavbeta3 and alphavbeta5 integrins are subject to regulation during angiogenesis. Fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF), two potent angiogenic factors released by tumors, induce the expression of these two integrins that collaborate with the FGF and VEGF receptors in angiogenic signaling pathways (4); disrupting angiogenic signaling by inactivation of either integrin or growth factor receptor leads to endothelial cell apoptosis (5). The integrins are often up-regulated on metastatic tumors as well, leading to enhanced invasion, proliferation, and tumor survival (6-9) by largely the same mechanisms operative in endothelial cells. For these reasons, the integrins and their regulatory mechanisms are attractive targets for the development of therapeutic drugs. Drugs that are currently being tested range from inhibitory integrin antibodies (e.g., Vitaxin [10], based on the inhibitory antibody LM609 [11]), to cyclic RGD peptides that interfere with ligand binding (e.g., cRGDfV, cilengitide, and ST1646 [12-15]), to peptidomimetics based on the RGD sequence (e.g., S247 [16]). These inhibitors have all been shown to disrupt the growth of solid tumors as well as angiogenesis.
###end p 4
###begin p 5
###xml 148 149 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 153 154 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 164 165 153 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 169 170 155 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 225 227 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 228 230 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 336 338 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 339 341 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 656 658 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 896 898 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 900 902 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
###xml 1076 1078 1059 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 1080 1082 1063 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 1251 1253 1234 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 1255 1257 1238 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 1339 1340 1318 1319 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1344 1345 1320 1321 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1383 1385 1359 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 1387 1389 1363 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 1708 1709 1680 1681 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1713 1714 1682 1683 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 1829 1831 1798 1800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
We have recently identified a regulatory mechanism by which syndecan-1 (Sdc1), a cell-surface matrix receptor, regulates the activation of the alphavbeta3 and alphavbeta5 integrins on mammary carcinoma cells and fibroblasts (17-20). The syndecans are multifunctional extracellular matrix receptors on the surface of all adherent cells (21-23). They anchor to the matrix via heparan sulfate (HS) glycosaminoglycan chains attached near the distal tips of their core proteins; these chains recognize "heparin-binding" domains present in most matrix ligands, including fibronectin (FN), laminins, vitronectin (VN), thrombospondin, and the fibrillar collagens (21). In addition, mounting evidence suggests that they assemble with and control the signaling of other cell surface receptors, including integrins. McFall et al. first described a "cell-binding domain" in the extracellular domain of Sdc4 (24, 25); this site has recently been shown to regulate beta1-containing integrins on mesenchymal cells, although the exact integrin target and regulatory mechanism remain unknown (26, 27). Recombinant Sdc2 extracellular domain alters adhesion mechanisms in colon carcinoma cells, suggesting that a regulatory site also exists in its extracellular domain (28, 29). More recently, we have shown that Sdc1 is necessary for activation of the alphavbeta3 integrin on mammary carcinoma cells (17, 20). Silencing Sdc1 expression, selective deletion of amino acids in its extracellular domain, or targeted competition with domain-specific antibodies or recombinant extracellular domain protein disrupts integrin activation and matrix recognition necessary for cell spreading and invasion. Similar activation of the alphavbeta5 integrin by Sdc1 occurs on B82L fibroblasts, which rely exclusively on this integrin for attachment to VN and FN (19). These extracellular syndecan-specific regulatory sites are readily accessible to therapeutic drugs and may hold promise as targets for combating tumorigenesis and other diseases in which their regulated mechanisms play a role.
###end p 5
###begin p 6
###xml 33 34 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 38 39 31 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 49 50 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 54 55 40 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 396 397 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 401 402 380 381 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 412 413 387 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 417 418 389 390 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 247 252 <span type="species:ncbi:10090">mouse</span>
###xml 257 262 <span type="species:ncbi:9606">human</span>
###xml 712 721 <span type="species:ncbi:10090">nude mice</span>
Given the importance of the alphavbeta3 and alphavbeta5 integrins in angiogenesis, we examined the possibility that Sdc1 regulates these integrins on vascular endothelial cells during tumor-induced angiogenesis. We found that Sdc1 is expressed by mouse and human endothelial cells in vitro, and is expressed during angiogenesis induced by FGF or VEGF in vitro and in vivo. We found that the alphavbeta3 and alphavbeta5 integrins associate with Sdc1 and that this association can be disrupted by a peptide called synstatin (SSTN) that is derived from the active site in the Sdc1 core protein. Furthermore, SSTN is an effective inhibitor of angiogenesis in vitro and in vivo, and of mammary carcinoma formation in nude mice. These results define the Sdc1 regulatory mechanism as a critical component of the angiogenic and tumorigenic process.
###end p 6
###begin title 7
RESULTS
###end title 7
###begin title 8
###xml 59 60 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 64 65 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
SSTN peptide inhibits Sdc1-mediated activation of the alphavbeta3 integrin on mammary carcinoma cells
###end title 8
###begin p 9
###xml 81 82 77 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 86 87 79 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 139 141 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 143 145 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 313 321 306 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 382 383 371 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 387 388 373 374 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 414 422 400 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 425 427 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 511 519 497 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 522 524 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 654 662 636 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 11 16 <span type="species:ncbi:9606">human</span>
###xml 213 218 <span type="species:ncbi:9606">human</span>
###xml 294 299 <span type="species:ncbi:10090">mouse</span>
MDA-MB-231 human mammary carcinoma cells rely on Sdc1 for activation of the alphavbeta3 integrin during their binding and spreading on VN (17, 20). Integrin activity is abolished by silencing Sdc1 expression with human-specific small interfering RNA (siRNA) but can be rescued by expression of mouse Sdc1 (mSdc1; Fig. 1 B). Cell binding and spreading on FN, which utilizes the alpha5beta1 integrin, is unaffected (Fig. 1 B) (20). Although native mSdc1 rescues integrin activity, deletion mutants (summarized in Fig. 1 A) (20) lacking a putative active site between amino acids 88 and 121 in its extracellular domain fail to rescue (see mSdc1Delta67-121; Fig. 1 B).
###end p 9
###begin p 10
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Derivation of SSTN peptide.</bold>
###xml 48 49 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 53 54 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 63 64 52 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 68 69 54 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 187 189 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 445 451 431 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 566 577 552 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;67-121</sup>
###xml 621 622 599 600 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 626 627 601 602 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 695 696 666 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 700 701 668 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 725 726 689 690 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 730 731 691 692 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 844 855 805 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;67-121</sup>
###xml 1064 1070 1013 1019 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 1147 1148 1088 1089 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1152 1153 1090 1091 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1399 1410 1337 1344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;67-121</sup>
###xml 1566 1573 1500 1507 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130.</sub>
###xml 1619 1620 1550 1551 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1764 1765 1683 1684 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 209 214 <span type="species:ncbi:10090">mouse</span>
###xml 786 791 <span type="species:ncbi:9606">human</span>
Derivation of SSTN peptide. (A) Summary of alphavbeta3 or alphavbeta5 integrin activation in cell attachment/spreading assays by either native or mutant mSdc1, mSdc4, or hSdc1 (reference 20). Numbers refer to mouse amino acid sequence. HS attachment sites in Sdc1 are amino acids 37, 45, and 47. Deletions identify a putative active site between amino acids 88-121; this site is contained in an SSTN peptide encompassing amino acids 82-130 (SSTN82-130). CD, cytoplasmic domain; GPI, glycosylphosphatidylinositol-linked lipid tail; TM, transmembrane domain. (B) mSdc1Delta67-121 deletion mutant fails to activate the alphavbeta3 integrin. Spreading of MDA-MB-231 cells for 2 h on either VN (alphavbeta3 dependent) or FN (alphavbeta3 independent) after silencing of hSdc1 expression with human-specific siRNA and rescue with either mSdc1 or mSdc1Delta67-121 deletion mutant. All images represent results from triplicate wells and three independent experiments. Bar, 50 microm. (C) Spreading of MDA-MB-231 cells on VN or FN in the presence or absence of 1 microM SSTN82-130. Bar, 50 microm. (D) SSTN disrupts Sdc1 coimmunoprecipitation with the alphavbeta3 integrin. hSdc1 is immunoprecipitated (using mAb B-B4) from MDA-MB-231 cells transfected with empty vector (NEO), and mSdc1 is immunoprecipitated (using mAb 281.2) from cells transfected with full-length mSdc1 or the mSdc1 deletion mutant (mSdc1Delta67-121). Immunoprecipitations were conducted in the presence or absence of GST, GST-S1ED (mS1ED if precipitating hSdc1 and hS1ED for mSdc1 precipitation), or SSTN82-130. Blots were probed for coprecipitation of beta3 integrin subunit (approximately105 kD) using Fire & Ice. Note the nonspecific band (*) that appears in all lanes, including the nonspecific IgG1 isotype control precipitations. Sdc1 runs as a band at approximately 85 kD after treatment with enzymes to remove its glycosaminoglycan chains; the core protein is visualized on the blots using mAb 3G10, which detects HS attachment stubs remaining on either the hSdc1 or mSdc1 core protein. Results are representative of at least three independent experiments.
###end p 10
###begin p 11
###xml 22 24 22 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 36 37 32 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 41 42 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 225 227 218 220 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 374 382 351 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 478 484 455 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 526 534 503 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
We showed previously (20) that alphavbeta3 integrin activity is lost in MDA-MB-231 cell adhesion/spreading assays in the presence of soluble, recombinant glutathione S-transferase-fused Sdc1 extracellular domain (GST-S1ED; ID50 of approximately3 microM). To test whether shorter peptides would mimic this activity, we derived a peptide spanning amino acids 82-130 of mSdc1 (Fig. 1 A). We call the inhibitory peptide sequence SSTN. Indeed, treatment of MDA-MB-231 cells with SSTN82-130 blocks their spreading on VN but not FN (Fig. 1 C).
###end p 11
###begin p 12
###xml 32 38 32 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 100 101 96 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 105 106 98 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 362 363 347 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 367 368 349 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 528 536 506 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 714 720 684 690 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 831 832 797 798 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 836 837 799 800 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 412 417 <span type="species:ncbi:9606">human</span>
We hypothesize that S1ED or SSTN82-130 may compete for an interaction between the S1ED and the alphavbeta3 integrin. To assess this, immunoprecipitations were performed using MDA-MB-231 cells expressing either empty vector (NEO), ectopic full-length mSdc1, or the mSdc1Delta67-121 deletion mutant that lacks the active site. Immunoblotting reveals that the alphavbeta3 integrin coprecipitates with either native human Sdc1 (hSdc1) or ectopic mSdc1, yet fails to associate with the mSdc1 mutant bearing the Delta67-121 deletion (Fig. 1 D). Coprecipitation is disrupted in the presence of either 30 microM GST-S1ED protein (using either mS1ED or hS1ED to avoid reactivity with the precipitating mAb) or 3 microM SSTN82-130 (which is not recognized by either precipitating mAb). These results suggest that these inhibitors block alphavbeta3 integrin activation by competitively displacing the integrin from an interaction with Sdc1.
###end p 12
###begin p 13
###xml 129 137 125 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 188 203 184 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, A and B</xref>
###xml 260 266 256 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 401 407 397 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">88-117</sub>
###xml 438 444 434 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 453 459 449 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">88-116</sub>
###xml 531 537 527 533 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">89-120</sub>
###xml 577 585 573 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 757 758 749 750 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 762 763 751 752 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 826 828 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
To define the minimal sequence required, we tested SSTN peptides (0-100 microM) carrying sequential N- and C-terminal deletions (Fig. 2 C) for their ability to block cell spreading on VN (Fig. 2, A and B). The minimal peptide required for full activity is SSTN92-119. Deletion of two or three residues from either end of this peptide either diminishes (approximately threefold loss in activity in SSTN88-117) or completely abolishes (SSTN94-119 and SSTN88-116) activity. A peptide representing the homologous region of hSdc1, hSSTN89-120, is equally effective as an inhibitor (Fig. 2 C), confirming that the active site is conserved between hSdc1 and mSdc1. Peptides displayed identical inhibitory effects on B82L fibroblasts, which rely solely on the alphavbeta5 integrin for adhesion and spreading on VN (unpublished data) (19).
###end p 13
###begin p 14
###xml 0 39 0 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Identification of minimal SSTN peptide.</bold>
###xml 205 211 197 203 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 217 223 209 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">88-117</sub>
###xml 229 235 221 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 244 250 236 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 537 538 521 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 542 543 523 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 646 652 627 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
Identification of minimal SSTN peptide. (A) Inhibition of MDA-MB-231 cell spreading on VN by SSTN. MDA-MB-231 cells were plated for 2 h on VN in the presence or absence of 3 microM mS1ED or 0.3 microM SSTN82-130, SSTN88-117, SSTN92-119, or SSTN94-119. Bar, 50 microm. (B) Quantification of cell spreading over a range of SSTN concentrations. Error bars represent SEM of triplicate points in each of two independent experiments. *, P < 0.05; **, P < 0.01). (C) Summary of SSTN peptides tested and their efficacy as inhibitors in the alphavbeta3-dependent MDA-MB-231 cell spreading assay. The active 92-119 sequence is underlined in the larger SSTN82-130 sequence.
###end p 14
###begin title 15
###xml 24 25 20 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 29 30 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 40 41 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 45 46 31 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
Sdc1 regulates the alphavbeta3 and alphavbeta5 integrins on vascular endothelial cells
###end title 15
###begin p 16
###xml 255 256 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 260 261 253 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 271 272 260 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 276 277 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 289 297 275 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 430 438 416 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 101 106 <span type="species:ncbi:9606">Human</span>
###xml 144 149 <span type="species:ncbi:9606">human</span>
###xml 300 305 <span type="species:ncbi:10090">Mouse</span>
###xml 380 385 <span type="species:ncbi:9606">human</span>
We next questioned whether the Sdc1 regulatory mechanism is operative on vascular endothelial cells. Human aortic endothelial cells (HAECs) and human dermal microvascular endothelial cells (HMEC-1s) express modest levels of Sdc1 and higher levels of alphavbeta3 and alphavbeta5 integrins (Fig. 3 A). Mouse aortic endothelial cells (MAECs) express higher levels of Sdc1 than their human counterparts but less of the two integrins (Fig. 3 A).
###end p 16
###begin p 17
###xml 28 29 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 33 34 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 44 45 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 49 50 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 0 91 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Expression of Sdc1 and &#945;<sub>v</sub>&#946;<sub>3</sub> and &#945;<sub>v</sub>&#946;<sub>5</sub> integrins in vascular endothelial cells.</bold>
###xml 107 108 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 112 113 91 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 123 124 98 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 128 129 100 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 252 253 220 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 257 258 222 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 268 269 229 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 273 274 231 232 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 423 429 369 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 435 441 381 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 450 456 396 402 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 547 548 478 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 614 615 530 531 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 707 708 607 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 712 713 609 610 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 722 723 615 616 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 727 728 617 618 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 761 767 651 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 877 883 767 773 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 892 898 782 788 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 1075 1081 965 971 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 1090 1091 976 977 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1095 1096 978 979 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1111 1117 994 1000 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 1125 1131 1008 1014 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 1240 1241 1119 1120 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1245 1246 1121 1122 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1316 1317 1188 1189 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1326 1327 1195 1196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1561 1562 1426 1427 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1566 1567 1428 1429 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1577 1578 1435 1436 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1582 1583 1437 1438 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 2165 2166 2008 2009 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 2170 2171 2010 2011 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 2190 2191 2026 2027 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 2195 2196 2028 2029 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
Expression of Sdc1 and alphavbeta3 and alphavbeta5 integrins in vascular endothelial cells. (A) Sdc1, alphavbeta3, or alphavbeta5 expression on HAECs, HMEC-1s, or MAECs is analyzed by flow cytometry. (B) SSTN competition for Sdc1 association with alphavbeta3 and alphavbeta5 integrins. hSdc1 is immunoprecipitated from HMEC-1s using mAb B-B4 in the absence or presence of 30 microM GST, 30 microM GST-S1ED, or 3 microM SSTN82-130, SSTN92-119, or SSTN94-119. Blots are probed for Sdc1 precipitation (approximately85 kD) and for coprecipitating beta3 integrin (approximately105 kD) subunit using Fire & Ice, and beta5 subunit with AB1926 (approximately100 kD). (C) Sdc1 associates directly with purified alphavbeta3 or alphavbeta5 integrin and is competed by SSTN92-119. Glutathione beads bearing GST-mS1ED were incubated with purified integrin in the presence or absence of SSTN92-119 and SSTN94-119. Integrin captured by the beads (or beads bearing GST alone) was detected on blots. Results are representative of at least three independent experiments. (D) Cross-linking SSTN92-119 to alphavbeta3 integrin. SSTN92-119 or SSTN94-119 prelabeled with Sulfo-SBED, a UV photoactivatable biotin transfer reagent, was incubated with purified alphavbeta3 integrin, and the transfer of the biotin label from SSTN to the alphav and beta3 subunits was assessed by Western blot either with (X-link +) or without (X-link -) photoactivation of the cross-linker. Results are representative of duplicate samples and at least two independent experiments. (E) Dependence of alphavbeta3 and alphavbeta5 integrin activation on Sdc1 in HMEC-1s. (left) Sdc1 expression in HMEC-1s was detected by mAb B-B4 in flow cytometry with or without silencing expression with Sdc1-specific siRNA. (right) HMEC-1s were plated on VN for 2 h with or without silencing hSdc1 expression. Bar, 50 microm. (F) Effect of Sdc1 silencing on endothelial cell attachment and spreading. Quantification of the percentage of spread HMEC-1s and HAECs (left) or attached cells (right) after treatment with control or hSdc1-specific siRNA to silence Sdc1 expression, or compared with treating with 30 microg/ml alphavbeta3 integrin and alphavbeta5 integrin blocking antibodies LM609 and P1F6, respectively, versus an isotype control antibody to block integrin activity. Note that these antibody concentrations allow half-maximal binding. Results are representative of triplicate wells and at least two independent experiments. Data are presented as means +/- SEM. **, P < 0.01.
###end p 17
###begin p 18
###xml 143 144 140 141 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 153 154 147 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 382 390 376 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 402 403 392 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 407 408 394 395 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 451 453 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 455 457 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 459 461 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 610 616 589 595 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 622 628 601 607 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 637 643 616 622 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 734 742 713 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 824 830 803 809 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 839 845 818 824 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 923 929 902 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 691 696 <span type="species:ncbi:9606">human</span>
To determine if Sdc1 and the integrins are in a regulatory complex, immunoprecipitates from HMEC-1s were probed for the coprecipitation of beta3 and beta5 integrin subunits with Sdc1. Both integrins coprecipitate with the syndecan and in seemingly equal proportions (quantified via comparison to a whole-cell lysate standard curve; not depicted) suggestive of a 1:1 correspondence (Fig. 3 B). The alphavbeta1 integrin, which is not regulated by Sdc1 (17, 19, 20), fails to coprecipitate (unpublished data). Immunoprecipitations were also conducted in the presence of either 30 microM GST-mS1ED or 3 microM SSTN82-130, SSTN92-119, or SSTN94-119; note that none of these are recognized by the human-specific mAb used for precipitation (Fig. 3 B). As expected, both the GST-mS1ED protein (but not GST alone) and the active SSTN82-130 and SSTN92-119 efficiently disrupt the Sdc1-integrin interactions, whereas the inactive SSTN94-119 is without effect.
###end p 18
###begin p 19
###xml 60 68 60 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 C</xref>
###xml 164 165 156 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 169 170 158 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 179 180 164 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 184 185 166 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 240 246 218 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 269 275 247 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 358 364 336 342 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 380 386 358 364 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 405 411 383 389 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 583 584 550 551 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 588 589 552 553 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 641 647 605 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 649 657 613 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
To test whether Sdc1 interacts directly with the integrins (Fig. 3 C), GST-mS1ED immobilized on glutathione beads was mixed in solution with 1 microM purified alphavbeta3 or alphavbeta5 integrin in the presence of 10 microM competitive SSTN92-119 or noncompetitive SSTN94-119. The purified integrins associate with S1ED, and their binding is competed by SSTN92-119 but not by SSTN94-119. In addition, SSTN92-119 prelabeled with photoactivatable Sulfo-SBED cross-linker (see Materials and methods) binds and transfers biotin label to both the alpha and beta subunits of purified alphavbeta3 integrin, whereas no transfer is detected with SSTN94-119 (Fig. 3 D).
###end p 19
###begin p 20
###xml 158 166 158 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 E</xref>
###xml 326 334 326 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 E</xref>
###xml 394 402 394 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 F</xref>
###xml 425 433 425 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 F</xref>
###xml 602 610 590 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 F</xref>
###xml 677 678 657 658 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 682 683 659 660 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 693 694 666 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 698 699 668 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 745 753 715 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 F</xref>
We next questioned whether the Sdc1 regulatory mechanism affects integrin activity on endothelial cells. Sdc1 expression was silenced in HMEC-1s using siRNA (Fig. 3 E, left), and the cells were plated on VN. Control siRNA-transfected cells bind and spread, but the spreading is blocked by >95% if Sdc1 expression is silenced (Fig. 3 E, right). Quantification of HMEC-1 and HAEC cell spreading (Fig. 3 F, left) or attachment (Fig. 3 F, right) shows that cell spreading is completely blocked, and cell attachment is blocked by 80% for both cell types when Sdc1 expression is reduced by approximately90% (Fig. 3 F). This is compared with combined treatment with 30 microg/ml alphavbeta3 and alphavbeta5 function-blocking antibodies LM609 and P1F6 (Fig. 3 F).
###end p 20
###begin p 21
###xml 183 191 183 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 426 427 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 431 432 424 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 442 443 431 432 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 447 448 433 434 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 573 581 559 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 584 586 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 635 641 617 623 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 663 664 637 638 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 668 669 639 640 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 679 680 646 647 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 684 685 648 649 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 831 837 795 801 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 1132 1138 1096 1102 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 1251 1259 1215 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
###xml 919 924 <span type="species:ncbi:9606">human</span>
We next tested whether the SSTN peptides inhibit integrin activation on the endothelial cells. HMEC-1s were plated on hSdc1 antibody (mAb B-B4), to which the cells attach and spread (Fig. 4 A). Our previous work using carcinoma cells showed that Sdc1 ligation by this method leads to integrin activation and cell spreading (17), even in the presence of EDTA to block potential ligand binding by the integrin. Indeed, the alphavbeta3 and alphavbeta5 integrins become activated when the cells attach to B-B4, detected by staining the cells with the ligand-mimetic Fab WOW-1 (Fig. 4 A) (30). However, treatment with either 0.5 microM SSTN82-130 or 30 microg/ml alphavbeta3 and alphavbeta5 integrin function-blocking antibodies (used as a comparative control) prevents both cell spreading and recognition by WOW-1, indicating that SSTN82-130 inhibits integrin activation. A similar experiment was conducted using suspended human umbilical vein endothelial cells (HUVECs) in which cell-surface Sdc1 is first decorated with hSdc1-specific mAb B-A38 and then clustered by addition of a secondary antibody in the presence or absence of SSTN82-130. WOW-1 binding shows that clustering of Sdc1 activates the integrin, and this is prevented by the SSTN peptide (Fig. 4 B).
###end p 21
###begin p 22
###xml 19 20 15 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 24 25 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 35 36 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 40 41 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 0 107 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Inhibition of &#945;<sub>v</sub>&#946;<sub>3</sub> and &#945;<sub>v</sub>&#946;<sub>5</sub> integrin activation in HMEC-1 vascular endothelial cells by SSTN.</bold>
###xml 131 132 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 136 137 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 267 273 242 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 595 596 562 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 779 785 742 748 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 887 888 846 847 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 892 893 848 849 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1085 1086 1037 1038 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1090 1091 1039 1040 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1101 1102 1046 1047 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1106 1107 1048 1049 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 1211 1212 1145 1146 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1216 1217 1147 1148 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1259 1260 1182 1183 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1264 1265 1184 1185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 1333 1339 1245 1251 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 1345 1351 1257 1263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 1360 1366 1272 1278 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 1822 1823 1726 1727 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1827 1828 1728 1729 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1838 1839 1735 1736 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1843 1844 1737 1738 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 1937 1938 1827 1828 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1942 1943 1829 1830 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1954 1955 1837 1838 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1959 1960 1839 1840 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 2063 2064 1943 1944 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 2075 2076 1955 1956 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2085 2086 1965 1966 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 2166 2172 2046 2052 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 2230 2231 2106 2107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 2235 2236 2108 2109 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 2256 2257 2125 2126 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 2261 2262 2127 2128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 2272 2273 2134 2135 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 2277 2278 2136 2137 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
Inhibition of alphavbeta3 and alphavbeta5 integrin activation in HMEC-1 vascular endothelial cells by SSTN. (A) Activation of alphavbeta3 integrin is blocked by SSTN. HMEC-1s plated for 2 h on hSdc1-specific antibody B-B4 in the presence or absence of 0.5 microM SSTN82-130 or 30 microg/ml of mAbs LM609 and P1F6. Integrin activation is shown by integrin-dependent cell spreading and by staining with the monovalent ligand-mimetic Fab antibody WOW-1. Results are representative of triplicate wells and two independent experiments. Bar, 20 microm. (B) Integrin activation by Sdc1 clustering. Sdc1+ HUVECs in suspension were treated with mAb B-A38 to engage Sdc1 and was treated with or without secondary antibody to cluster the syndecan in the presence or absence of 1 microM SSTN82-130. Quantification of WOW-1 binding via flow cytometry was used to measure the levels of activated alphavbeta3 integrin. Results are representative of duplicate samples and at least two independent experiments. MFI, mean fluorescent intensity. (C) HMEC-1 spreading on VN is dependent on integrins alphavbeta3 and alphavbeta5 and is blocked by SSTN. HMEC-1s plated on VN for 2 h were treated with 30 microg/ml of mAb LM609 (alphavbeta3 blocker), 30 microg/ml of mAb P1F6 (alphavbeta5 blocker), or both antibodies, or 5 microM mS1ED, or 0.5 microM SSTN82-130, SSTN92-119, or SSTN94-119 as competitive inhibitors. The SSTN inhibitors were also tested on cells plated on FN as a negative control (right column). Results are representative of triplicate wells and at least two independent experiments. Bar, 50 microm. (D) Quantification of cell spreading. The percentage of spread HMEC-1s and HAECs was quantified after plating for 2 h on VN in the presence of mS1ED or SSTN peptides. **, P < 0.01. (E) Sdc1-negative HUVECs have activated alphavbeta3 and alphavbeta5 integrin but are insensitive to inhibitory SSTN peptide treatment. Expression of Sdc1, alphavbeta3, and alphavbeta5 are quantified by flow cytometry (left) in two isolates of HUVECs, one of which is Sdc1 negative (Sdc1-). The Sdc1+ and Sdc1- HUVECs are compared in cell spreading assays on VN, using competition with SSTN82-130, silencing Sdc1 expression with siRNA, and blocking alphavbeta3 alone or both alphavbeta3 and alphavbeta5 integrins with blocking antibodies LM609 and P1F6 (right). Results are representative of triplicate wells and at least two independent experiments. Data are presented as means +/- SEM. **, P < 0.01.
###end p 22
###begin p 23
###xml 247 248 243 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 252 253 245 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 277 278 266 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 282 283 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 350 358 336 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
###xml 387 393 373 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 482 488 456 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 508 514 478 484 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 610 618 580 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
###xml 687 695 657 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
###xml 899 907 865 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 D</xref>
###xml 920 922 886 888 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1021 1027 971 977 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 1036 1042 986 992 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 1218 1226 1164 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
Blockade of integrin activation with the SSTN peptides is also shown by disrupted cell attachment and spreading on VN. HMEC-1s are dependent on both integrins, as partial spreading is observed if one integrin is blocked (e.g., LM609 to block alphavbeta3, or P1F6 to block alphavbeta5), but a complete block occurs in the presence of both antibodies (Fig. 4 C). Although the inactive SSTN94-119 is without effect even at 100 microM, addition of either 5 microM mS1ED, 0.5 microM SSTN82-130, or 0.5 microM SSTN92-119 blocks spreading on VN as effectively as (if not better than) the combined antibody treatment (Fig. 4 B). Attachment and spreading on FN is not affected by these peptides (Fig. 4 C) or by the integrin blocking antibodies (unpublished data). Quantification of these results shows that competition with mS1ED at 1-3-microM concentrations reduces HMEC-1 cell spreading on VN by >80-90% (Fig. 4 D), with an ID50 of approximately1 microM for HAECs, which are more resistant than the HMEC-1s. In comparison, SSTN82-130 and SSTN92-119 display an equivalent inhibitory activity when used at a 10-fold lower concentration, displaying significant inhibitory properties in the 0.1-0.3-microM range. As observed in Fig. 4 C, cell adhesion is also disrupted at the higher inhibitory concentrations and can be prevented altogether by adding increased concentrations of the peptides (unpublished data).
###end p 23
###begin p 24
###xml 216 217 216 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 304 305 304 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 336 344 336 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 E</xref>
###xml 366 367 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 376 377 376 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 417 418 413 414 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 422 423 415 416 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 433 434 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 438 439 424 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 518 526 504 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 E</xref>
###xml 654 655 636 637 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 659 660 638 639 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 670 671 645 646 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 675 676 647 648 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 704 710 676 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 745 746 717 718 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 832 833 804 805 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 890 891 862 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 970 971 942 943 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1174 1175 1142 1143 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1179 1180 1144 1145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1190 1191 1151 1152 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1195 1196 1153 1154 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
Lastly, the specificity of the SSTN peptides for this Sdc1-regulated mechanism was demonstrated comparing HUVECs that are either positive or negative for Sdc1 expression. Although primary HUVECs do express Sdc1 (Sdc1+), one isolate of these cells that we obtained failed to express the proteoglycan (Sdc1-), as shown by flow cytometry (Fig. 4 E, left); both the Sdc1+ and Sdc1- cells express identical levels of alphavbeta3 and alphavbeta5 integrins. Somewhat surprisingly, both sets of cells attach and spread on VN (Fig. 4 E, right), both are inhibited by mAb LM609, and both are inhibited further by addition of mAbs LM609 and P1F6 to block both alphavbeta3 and alphavbeta5 integrins. Addition of SSTN82-130 inhibits the spreading of the Sdc1+ HUVECs, similar to its effect on HMEC-1s and HAECs, but is without effect on the Sdc1- HUVECs. Similarly, silencing Sdc1 expression on the Sdc1+ HUVECs blocks their spreading, whereas the siRNA is without effect on the Sdc1- cells, as would be expected. This suggests that an alternative activation mechanism exists in the absence of Sdc1 gene expression, and that the SSTN peptide is specific only for the Sdc1-regulated alphavbeta3 and alphavbeta5 activation mechanism.
###end p 24
###begin title 25
SSTN inhibits angiogenesis in vitro and in vivo
###end title 25
###begin p 26
###xml 337 345 337 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 371 372 367 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 376 377 369 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 387 388 376 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 392 393 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 449 457 435 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 622 623 604 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 627 628 606 607 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 638 639 613 614 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 643 644 615 616 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 656 664 628 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 B</xref>
###xml 767 775 739 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 C</xref>
###xml 820 822 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 1284 1285 1252 1253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1291 1292 1256 1257 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1302 1303 1264 1265 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 1420 1422 1375 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">32</xref>
###xml 1616 1617 1567 1568 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1621 1622 1569 1570 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1628 1629 1572 1573 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1633 1634 1574 1575 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 194 199 <span type="species:ncbi:10090">mouse</span>
###xml 436 441 <span type="species:ncbi:10090">mouse</span>
###xml 503 508 <span type="species:ncbi:10090">mouse</span>
###xml 742 747 <span type="species:ncbi:10090">mouse</span>
As a first step in understanding a potential role for Sdc1 in angiogenesis in vivo, we questioned whether Sdc1 was expressed either in the endothelial lining of resting blood vessels (using the mouse aorta) or in microvessels arising from the aorta in response to angiogenic stimuli. As we found when examining the MAEC line in culture (Fig. 3 A), both Sdc1 and the alphavbeta3 and alphavbeta5 integrins are present even on the resting mouse aorta (Fig. 5 A). In addition, microvessels growing out from mouse aortic explants over 7 d in response to FGF-2 stain positively for Sdc1, which appears coexpressed with the alphavbeta3 and alphavbeta5 integrins (Fig. 5 B). In addition, Sdc1 expression is observed in activated endothelial cells of mouse tumor vasculature (Fig. 5 C). Tumors derived from Wnt-1 overexpression (31) in the mammary gland show a high degree of vascularization, identified as internal networks lined by a thick cell layer that stains intensely for Sdc1 and for platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31), indicative of activated endothelium. In fact, Sdc1 expression in these cells swamps out the positive staining for Sdc1 seen in the mammary epithelial cells, which are known to be Sdc1 positive. These same cell layers are positive for alphav, beta3, and beta5 integrin subunits. A similar finding is seen in mammary tumors arising from overexpression of DeltaN89beta-catenin (32). Although the vascularization is not as extensive as in the Wnt-1-induced tumors, there are clear thickened layers of activated endothelial cells that are positive for PECAM-1, Sdc1, and alphavbeta3/alphavbeta5 integrin in these mammary tumors.
###end p 26
###begin p 27
###xml 18 19 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 23 24 16 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 30 31 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 35 36 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 0 95 0 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sdc1 and the &#945;<sub>v</sub>&#946;<sub>3</sub>/&#945;<sub>v</sub>&#946;<sub>5</sub> integrins are coexpressed in normal and tumor vasculature.</bold>
###xml 175 176 157 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 191 192 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 210 211 186 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 533 534 502 503 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 542 543 508 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 939 940 897 898 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 946 947 901 902 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 956 957 908 909 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 126 131 <span type="species:ncbi:10090">mouse</span>
###xml 164 169 <span type="species:ncbi:10090">mouse</span>
###xml 517 520 <span type="species:ncbi:10116">rat</span>
###xml 583 589 <span type="species:ncbi:9986">rabbit</span>
###xml 651 656 <span type="species:ncbi:10090">mouse</span>
###xml 1048 1052 <span type="species:ncbi:10090">mice</span>
###xml 1064 1068 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1144 1148 <span type="species:ncbi:10090">mice</span>
Sdc1 and the alphavbeta3/alphavbeta5 integrins are coexpressed in normal and tumor vasculature. (A) En face staining of fixed mouse aorta for mSdc1 (mAb 281.2) and mouse alphav (AB1923), beta3 (AB1932), or beta5 (AB1926) integrin subunits. Endothelial cells are present as cords and are identified by mAb 390 (anti-PECAM-1/CD31) staining. Results are representative of at least three independent experiments. Bar, 50 microm. (B) Sdc1 expression in aortic explants. Staining with mSdc1-specific mAb (green) or control rat IgG and beta3 or beta5 integrin-specific IgG (red) or control rabbit IgG in microvessels induced by 30 ng/ml FGF-2 after 7 d from mouse aortic explants grown in type-I collagen gels. PECAM-1 staining of microvessels is also shown. Results are representative of triplicate wells and at least two independent experiments. Bar, 50 microm. (C) Expression of Sdc1 and integrins in tumor vasculature. PECAM-1, Sdc1, or alphav, beta3, or beta5 integrin subunits are stained in frozen sections of spontaneous mammary tumors arising in mice because of MMTV promoter-driven expression of ectopic Wnt-1 or DeltaN89beta-catenin (three mice each). Arrows point to identical structures in the PECAM and Sdc1 or integrin costained panels to orient the reader. Results are representative of at least three independent experiments. Bar, 50 microm.
###end p 27
###begin p 28
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 632 638 632 638 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 687 688 683 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 711 719 707 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 A</xref>
###xml 1127 1135 1123 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
###xml 133 138 <span type="species:ncbi:10090">mouse</span>
###xml 188 193 <span type="species:ncbi:10090">mouse</span>
###xml 321 326 <span type="species:ncbi:10090">mouse</span>
###xml 676 681 <span type="species:ncbi:10090">mouse</span>
To test the importance of the Sdc1 regulatory mechanism during angiogenesis, we tested the activity of SSTN peptides in the in vitro mouse aortic ring outgrowth assay (33) and the in vivo mouse corneal pocket angiogenesis model (34). The aortic outgrowth assay was used to quantify microvessel outgrowth from segments of mouse aorta explanted to collagen gels in the presence of either VEGF or FGF-2, and incubated in the presence of either recombinant mS1ED protein or SSTN peptides. Microvessels are observed growing out of the aortic explants over 7 d in response to VEGF, and this is blocked by increasing concentrations of SSTN82-130 or by an antibody (M9) that inhibits mouse alphav-containing integrins (Fig. 6 A). Single cells observed to be migrating out from the explants in the presence of SSTN or the blocking antibody are likely to be fibroblasts and pericytes. Indeed, desmin staining shows that pericytes line up on the PECAM-positive microvessels in the absence of SSTN and continue to migrate out from the explant in a disorganized fashion when SSTN prevents the outgrowth of PECAM-positive endothelial cells (Fig. 6 B).
###end p 28
###begin p 29
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SSTN blocks microvessel outgrowth from mouse aortic explants.</bold>
###xml 117 118 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 270 276 262 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 298 299 282 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 569 575 553 559 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 594 600 578 584 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 39 44 <span type="species:ncbi:10090">mouse</span>
###xml 326 331 <span type="species:ncbi:10090">mouse</span>
###xml 627 630 <span type="species:ncbi:10116">rat</span>
###xml 660 663 <span type="species:ncbi:10116">rat</span>
###xml 699 704 <span type="species:ncbi:10090">mouse</span>
###xml 733 738 <span type="species:ncbi:10090">mouse</span>
###xml 1199 1204 <span type="species:ncbi:10090">mouse</span>
###xml 1245 1250 <span type="species:ncbi:10090">mouse</span>
SSTN blocks microvessel outgrowth from mouse aortic explants. (A) Blockade of VEGF-induced outgrowth by SSTN or alphav integrin blocking antibody. Aortic explants to type-I collagen are treated with 50 ng/ml VEGF for 7 d in the presence of 0, 0.1, 0.3, and 1 microM SSTN82-130 or 10 microg/ml alphav blocking antibody M9 or a mouse IgG control. Arrows denote microvessels. Insets show full aortic ring with dashed box to identify the magnified area shown. Bar, 0.5 mm. (B) Outgrowth of pericytes and endothelial cells. Aortic rings grown as in A in the presence of SSTN94-119 (inactive) or SSTN92-119 (active) are stained with rat anti-PECAM-1 (or nonspecific rat IgG) to mark endothelial cells, or mouse anti-desmin (or nonspecific mouse IgG) to identify pericytes. Note that SSTN affects endothelial but not pericyte outgrowth. Bar, 50 microm. (C and D) Quantification of total microvessel outgrowth in VEGF-treated (C) and FGF-treated (D) rings. The total microvessel outgrowth is compared for rings treated with 50 ng/ml VEGF or 30 ng/ml FGF. Each bar represents the total microvessel outgrowth per explant for six explants (+/-SD). Rings were incubated in medium containing either no addition, mouse S1ED, SSTN peptides, mAb M9, or control mouse IgG. Results are representative of at least three independent experiments. **, P < 0.01.
###end p 29
###begin p 30
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">35</xref>
###xml 348 363 348 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6, C and D</xref>
###xml 469 477 461 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 C</xref>
###xml 503 511 495 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 D</xref>
###xml 634 640 610 616 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 649 655 625 631 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 776 778 752 754 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 858 860 818 820 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 963 969 923 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4</xref>
###xml 1051 1052 1003 1004 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1115 1116 1063 1064 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1120 1121 1065 1066 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1131 1132 1072 1073 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1136 1137 1074 1075 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 1149 1155 1087 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
Quantification of vessel outgrowth shows that SSTN inhibits both VEGF- and FGF-stimulated outgrowth. Although some vessel outgrowth is observed in the absence of exogenous angiogenic agents, likely caused by VEGF released by the pericytes growing out from the explant (35), the outgrowth is greatly increased by supplementation with FGF-2 or VEGF (Fig. 6, C and D). Addition of recombinant S1ED blocks VEGF-induced outgrowth by >70% at 10 microM and >95% at 30 microM (Fig. 6 C). FGF-induced outgrowth (Fig. 6 D) requires slightly higher inhibitory concentrations (approximately30 microM mS1ED for 70% inhibition). In comparison, SSTN82-130 and SSTN92-119 are 10-30-fold more potent that mS1ED and show equivalent inhibition of VEGF- or FGF-induced outgrowth, displaying an ID50 of approximately0.1 microM. These concentrations are nearly identical to the ID50's displayed in the in vitro cell attachment and spreading assays with HMEC-1s and HAECs (compare with Fig. 4) and are comparable to the effects of 10 microg/ml of the function-blocking alphav integrin mAb M9, which inhibits the activity of both the alphavbeta3 and alphavbeta5 integrins (Fig. 6).
###end p 30
###begin p 31
###xml 78 84 78 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7</xref>
###xml 719 725 711 717 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 733 739 725 731 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 797 799 789 791 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 829 837 805 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 A</xref>
###xml 843 851 819 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 C</xref>
###xml 1035 1043 1011 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 B</xref>
###xml 1183 1185 1155 1157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1339 1345 1295 1301 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">88-116</sub>
###xml 1353 1359 1309 1315 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 1410 1418 1366 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 A</xref>
###xml 1424 1432 1380 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 C</xref>
###xml 251 256 <span type="species:ncbi:10090">mouse</span>
###xml 944 950 <span type="species:ncbi:9986">rabbit</span>
The SSTN peptides were also tested in the in vivo corneal angiogenesis assay (Fig. 7). Poly(2-hydroxyethyl methacrylate) (Poly-HEMA) pellets containing 67 ng FGF-2 and 250 ng sucralfate (used as a slow-release agent) were implanted into the avascular mouse cornea. After 7 d, fluorescent dextran was injected retroorbitally to highlight the vascular system at the time of sacrifice. Visual inspection of either the eye or the dissected cornea shows significant vessel growth toward the implanted pellet from the margin of the cornea. To test the effects of blocking Sdc1, SSTN peptides were delivered systemically via Alzet osmotic pumps (see Materials and methods). Pumps delivering 1 microl/h of up to 100 microM SSTN82-130 or SSTN92-119 achieved a nearly total block of angiogenesis, with an ID50 of approximately3-10 microM (Fig. 7 A; and Fig. 7 C, left). To correlate this with the active concentration in the plasma, we took advantage of rabbit polyclonal antibodies generated against mS1ED that detect active SSTN on dot blots (Fig. 7 B). This shows that SSTN accumulates to 125-150 nM in the blood after 1 wk of treatment with 10 microM SSTN. This correlates well with the ID50 of approximately100 nM observed in vitro and suggests a clearance rate of 10-13 h in the plasma. In contrast, delivery of 100 microM of the inactive SSTN88-116 or SSTN94-119 in Alzet pumps has no effect on vessel outgrowth (Fig. 7 A; and Fig. 7 C, left).
###end p 31
###begin p 32
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SSTN blocks FGF-induced corneal angiogenesis in vivo.</bold>
###xml 381 387 369 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 393 399 381 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 408 414 396 402 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 852 858 840 846 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 901 907 885 891 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 1130 1136 1110 1116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 1402 1405 1382 1385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1608 1611 1586 1589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1752 1758 1726 1732 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 1768 1771 1742 1745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1860 1861 1830 1831 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 228 233 <span type="species:ncbi:10090">mouse</span>
###xml 747 751 <span type="species:ncbi:10090">mice</span>
###xml 1008 1014 <span type="species:ncbi:9986">rabbit</span>
###xml 1060 1065 <span type="species:ncbi:10090">mouse</span>
###xml 1085 1089 <span type="species:ncbi:10090">mice</span>
###xml 1407 1411 <span type="species:ncbi:10090">mice</span>
###xml 1612 1616 <span type="species:ncbi:10090">mice</span>
###xml 1622 1626 <span type="species:ncbi:10090">mice</span>
###xml 1772 1776 <span type="species:ncbi:10090">mice</span>
###xml 1784 1788 <span type="species:ncbi:10090">mice</span>
SSTN blocks FGF-induced corneal angiogenesis in vivo. (A) Angiogenic outgrowth in response to FGF. 0.125 microl of Poly-HEMA pellets (P in the images) containing 67 ng FGF-2 and 250 ng sucralfate were implanted in the avascular mouse cornea for 7 d. Alzet osmotic pumps were implanted subcutaneously on the backs of the animals and deliver 1 microl/h PBS or PBS plus 30 microM SSTN82-130, SSTN92-119, or SSTN94-119. Fluorescent dextran is injected intravenously 1-2 min before sacrifice, and angiogenesis is imaged either in the intact eye or by fluorescence of blood vessels in the dissected cornea (insets). Vessels in the iris can be observed but can be distinguished from angiogenesis in the cornea. Results are representative of at least six mice per treatment condition. The experiment was repeated independently three times. Bars, 1 mm. (B) SSTN82-130 concentration in the serum. 11 microM SSTN82-130 was spotted in triplicate on nitrocellulose with threefold dilutions, detected with Sdc1 polyclonal rabbit antibody (left), and compared with undiluted mouse serum derived from mice treated with 30, 10, 3, or 0 microM SSTN82-130 in PBS (middle). The estimated concentration of SSTN in the serum is plotted versus its starting concentration in the pump (right). Data are representative of three independent experiments. (C) Quantification of corneal angiogenesis in wild-type and Sdc1-null (Sdc1-/-) mice. Mean total vessel outgrowth in the presence or absence of SSTN (concentration in the pump is shown) is quantified and expressed relative to the PBS control set at 100% (+/-SD). Wild-type and Sdc1-/- mice (six mice per data point for each cohort from three independent experiments) were directly compared using treatments of 100 microM SSTN82-130. The Sdc1-/- mice (three mice per data point for one experiment) were also treated with 22.7 mM alphav integrin-specific cRGDfV inhibitory peptide or inactive cRADfV peptide. Data are presented as means +/- SEM. *, P < 0.05; **, P < 0.01.
###end p 32
###begin p 33
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 178 181 178 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 242 250 242 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 C</xref>
###xml 395 396 391 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 544 546 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 548 550 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 623 629 615 621 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 657 663 649 655 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 746 754 738 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 C</xref>
###xml 843 844 831 832 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 848 849 833 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 859 860 840 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 864 865 842 843 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 886 889 864 867 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
###xml 530 535 <span type="species:ncbi:10090">mouse</span>
###xml 740 744 <span type="species:ncbi:10090">mice</span>
###xml 890 895 <span type="species:ncbi:10090">mouse</span>
We also tested SSTN peptide on male BALB/c Sdc1 knockout mice, as it has been previously reported that angiogenesis is not blocked in this animal (36). Indeed, we found that Sdc1-/- mice display corneal vessel outgrowth in response to FGF-2 (Fig. 7 C, right, blue bars). In addition, this vessel outgrowth is reduced >60% by circulating cRGDfV, a cyclic RGD inhibitory peptide specific for alphav integrins, compared with an inactive cRADfV peptide. This duplicates the extent of inhibition observed for this RGD peptide in other mouse models (15, 37). However, the angiogenesis is not blocked by as much as 100 microM SSTN82-130; this concentration of SSTN82-130 inhibits angiogenesis by 90% in a parallel experiment with wild-type BALB/c mice (Fig. 7 C, right, red bars). Thus, a compensatory mechanism exists for the activation of the alphavbeta3 and alphavbeta5 integrin in the Sdc1-/- mouse that is insensitive to the inhibitory SSTN peptide.
###end p 33
###begin p 34
###xml 13 19 13 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 69 75 69 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8</xref>
###xml 338 344 334 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 573 579 549 555 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 655 670 631 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8, A and B</xref>
###xml 908 916 884 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8 C</xref>
###xml 1121 1129 1093 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8 D</xref>
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 176 185 <span type="species:ncbi:10090">nude mice</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
Finally, SSTN82-130 was tested in an in vivo orthotopic tumor model (Fig. 8). MDA-MB-231 human mammary carcinoma cells were injected subcutaneously into female, athymic BALB/c nude mice. Palpable tumors were allowed to form for 1 wk after injection, at which time Alzet pumps delivering 0.25 microl/h of either PBS alone (control) or SSTN82-130 were implanted. Tumor growth was monitored for an additional 4 wk before sacrifice. Treatment with 120 microM (0.37 +/- 0.02 microM in the serum; not depicted) or 400 microM (1.87 +/- 0.06 microM in the serum; not depicted) SSTN82-130 results in a significant reduction in tumor size relative to control mice (Fig. 8, A and B). Moreover, staining the tumor sections for PECAM-1 or desmin shows a significant reduction in the number of tumor vessels in the SSTN-treated tumors; both endothelial cells and pericytes are observed, but in reduced numbers of vessels (Fig. 8 C). Quantification of angiogenesis either by measuring total vessel length in the sections or total PECAM-1 positive staining shows an 11-fold reduction in animals bearing pumps containing 400 microM SSTN (Fig. 8 D).
###end p 34
###begin p 35
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Inhibition of tumor growth by SSTN.</bold>
###xml 189 195 185 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 312 318 300 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 1147 1153 1131 1137 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 117 126 <span type="species:ncbi:10090">nude mice</span>
###xml 350 359 <span type="species:ncbi:10090">nude mice</span>
###xml 674 677 <span type="species:ncbi:10116">rat</span>
###xml 715 719 <span type="species:ncbi:9925">goat</span>
###xml 725 728 <span type="species:ncbi:10116">rat</span>
###xml 808 813 <span type="species:ncbi:10090">mouse</span>
###xml 1114 1118 <span type="species:ncbi:10090">mice</span>
###xml 1219 1223 <span type="species:ncbi:10090">mice</span>
Inhibition of tumor growth by SSTN. (A) Effects of SSTN on tumor growth. Isolated 5-wk-old tumors from female BALB/c nude mice bearing Alzet pumps delivering PBS or PBS plus 400 microM SSTN82-130. (B) Quantification of tumor growth over time. Alzet pumps containing PBS, or PBS with 120 microM or 400 microM SSTN82-130 were implanted on the flank of nude mice with 1-wk-old subcutaneous MDA-MB-231 cell tumors (arrow and baseline tumor size). Tumor size was measured at weekly intervals for 4 wk of each ensuing treatment. **, P < 0.01. (C) Detection of tumor vasculature in frozen OCT-embedded sections. Sections are stained with anti-PECAM-1 (mAb MEC 13.3) or nonspecific rat IgG2A and Alexa Fluor 488-conjugated goat anti-rat secondary antibody to detect endothelial cells, and anti-desmin or nonspecific mouse IgG1 and Alexa Fluor 546-conjugated secondary antibody to detect pericytes. Bars, 50 microm. (D) Quantification of total PECAM-positive vessels. Relative angiogenesis was quantified by totaling either vessel length (left) or total PECAM-1 staining intensity (right) in frozen sections of tumors from mice treated with or without SSTN82-130. Data are from two independent experiments with a minimum of six mice per data point in each, and are presented as means +/- SEM. **, P < 0.01.
###end p 35
###begin title 36
DISCUSSION
###end title 36
###begin p 37
###xml 72 73 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 77 78 70 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 88 89 77 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 93 94 79 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 432 434 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">38</xref>
###xml 435 437 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">41</xref>
###xml 517 519 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">42</xref>
###xml 589 591 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">39</xref>
###xml 625 627 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib43">43</xref>
###xml 708 710 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib44">44</xref>
###xml 845 847 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 506 509 <span type="species:ncbi:10116">rat</span>
###xml 611 617 <span type="species:ncbi:9986">rabbit</span>
###xml 838 843 <span type="species:ncbi:10090">mouse</span>
Previous work described a dependence on Sdc1 for activation of the alphavbeta3 and alphavbeta5 integrins. This raises the question of whether this regulatory mechanism exists on the vascular endothelium during angiogenesis. Although expression of Sdc1 in the vascular endothelium has not been studied extensively, several reports indicate that it is expressed in the endothelium of newly formed vessels in wound granulation tissue (38-41) and the endothelial lining of intramyocardial blood vessels in the rat heart (42); however, no expression is seen in blood vessels in unwounded skin (39) nor in the normal rabbit aorta (43), suggesting that its expression may be regulated, perhaps by ephrin signaling (44). A role in angiogenesis, however, is seemingly cast in doubt by the finding that angiogenesis is not impeded in the Sdc1-null mouse (36).
###end p 37
###begin p 38
###xml 205 206 201 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 210 211 203 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 221 222 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 226 227 212 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 672 673 654 655 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 677 678 656 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 838 840 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib45">45</xref>
###xml 841 843 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">47</xref>
###xml 269 274 <span type="species:ncbi:10090">mouse</span>
Our findings suggest that Sdc1 is indeed expressed in the vascular endothelium and that its core protein has an important regulatory role during the angiogenic process. It is detected, along with the alphavbeta3 and alphavbeta5 integrins, in cultured MAECs, in resting mouse aorta, and in angiogenic aortic microvessels in vitro and tumor vasculature in vivo. Although we have not investigated directly whether or not Sdc1 expression is up-regulated during angiogenesis, it does display intense staining in the endothelial cells undergoing angiogenesis in the aortic ring outgrowth assay and in mammary tumors. Up-regulated expression of Sdc1 would mimic that of the alphavbeta3 integrin, which displays low or nonexistent expression in most adult tissues and is dramatically up-regulated in the vascular endothelium during angiogenesis (45-47). Most importantly, blocking Sdc1 expression or competitively blocking its interaction with these integrins using SSTN serves to inactivate the integrins and block endothelial cell attachment, spreading, and invasion/outgrowth in vitro, as well as angiogenesis and tumor growth in vivo. The regulatory mechanism remains unknown, but it appears to rely on a direct interaction between the integrins and Sdc1.
###end p 38
###begin p 39
###xml 169 170 165 166 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 174 175 167 168 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 185 186 174 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 190 191 176 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 333 334 315 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 338 339 317 318 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 349 350 324 325 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 354 355 326 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 1104 1106 1076 1078 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 68 73 <span type="species:ncbi:10090">mouse</span>
###xml 522 526 <span type="species:ncbi:10090">mice</span>
###xml 723 728 <span type="species:ncbi:10090">mouse</span>
Interestingly, our findings do confirm the ability of the Sdc1-null mouse to mount a seemingly normal angiogenic response, a response that appears dependent on the alphavbeta3 and alphavbeta5 integrins despite the absence of Sdc1. This finding is matched by an isolate of HUVECs that are also Sdc1 negative. They display active alphavbeta3 and alphavbeta5 integrins, but unlike their Sdc1-positive counterparts, they are not dependent on Sdc1 and are unaffected by SSTN. In these Sdc1-negative cells (and in the Sdc1-null mice), integrin activation presumably occurs via a compensatory mechanism that is activated in the absence of Sdc1 gene expression. This not only explains why angiogenesis is observed in the Sdc1-null mouse, but it also provides a strong argument for the specificity of the SSTN peptide. That is, the peptide appears to compete for a specific interaction of Sdc1 with these integrins that is essential for their activation on Sdc1-expressing cells. If this mechanism is absent, the peptide has no apparent off-target effects even at concentrations up to 100-fold greater than its ID50.
###end p 39
###begin p 40
###xml 186 187 182 183 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 191 192 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 202 203 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 207 208 193 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 292 293 274 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 297 298 276 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 435 437 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">48</xref>
###xml 567 570 542 545 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IIb</sub>
###xml 574 575 546 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 585 586 553 554 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 590 591 555 556 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 702 704 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib49">49</xref>
###xml 706 708 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib50">50</xref>
Although the mechanisms of integrin activation have received considerable scrutiny, especially during processes such as platelet activation and in angiogenesis, the reliance of the alphavbeta3 and alphavbeta5 integrins on Sdc1 during angiogenesis has not been appreciated until now. The alphavbeta3 integrin has been shown previously to associate with other membrane proteins, with some leading to enhanced activation of the integrin (48). Integrin-associated protein (also known as CD47) presents an intriguing comparison to Sdc1 in that it associates with the alphaIIbbeta3 and alphavbeta3 integrins via its extracellular domain, and this interaction alone is sufficient to activate these integrins (49, 50).
###end p 40
###begin p 41
###xml 138 141 134 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IIb</sub>
###xml 145 146 138 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 156 157 145 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 161 162 147 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 450 452 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib51">51</xref>
###xml 453 455 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib55">55</xref>
###xml 486 487 468 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 491 492 470 471 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 599 601 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib56">56</xref>
###xml 656 657 632 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 760 762 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib57">57</xref>
###xml 764 766 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib58">58</xref>
###xml 883 885 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib59">59</xref>
###xml 974 976 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">48</xref>
The activation of an integrin typically refers to a conformation change that dramatically increases ligand binding affinity, and the alphaIIbbeta3 and alphavbeta3 integrins have been used as models to begin to understand the activation mechanism. It proceeds through two or more activation states, each resulting in a conformational change in the integrin's extracellular domain in response to intracellular signals and extracellular ligand binding (51-55). In a current model for alphavbeta3 activation, the inactive integrin is in a bent configuration and opens like a switchblade when activated (56). This occurs in response to talin binding to the beta3 integrin cytoplasmic domain and breaking of the salt bridge that maintains the inactive conformation (57, 58). However, it is also enhanced by oligomerization of the integrin subunits within the plane of the plasma membrane (59), and by extracellular interactions with matrix ligands and/or other membrane proteins (48).
###end p 41
###begin p 42
###xml 62 63 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 67 68 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 78 79 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 83 84 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 412 414 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 848 849 830 831 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 853 854 832 833 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 867 868 842 843 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 872 873 844 845 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
Our data now suggest that the active conformation of the alphavbeta3 and alphavbeta5 integrins is favored by their direct association with Sdc1. The integrins are activated by plating endothelial cells on Sdc1 antibody, or by antibody-induced clustering of Sdc1 on suspended endothelial cells, as shown in this study by the binding of the ligand-mimetic Fab WOW-1; this has also been shown with carcinoma cells (20). The activation that occurs when Sdc1 is engaged by antibody is not blocked by depletion of divalent cations that are otherwise necessary for ligand binding by the integrin, indicating that Sdc1 is engaged as a membrane coreceptor, not as a ligand. The fact that WOW-1 is a monovalent Fab indicates that the activation is a true increase in integrin affinity rather than increased avidity. As we now show that the syndecan and alphavbeta3 and/or alphavbeta5 integrins form a complex, likely via lateral interactions of their extracellular domains, it seems apparent that clustering Sdc1 leads to clustering of the integrins as well. It is possible that the clustering brings together kinases associated either with the integrin or the Sdc1, initiating kinase transphosphorylation and activation of signaling pathways that activate the integrin through talin. In vivo, clustering would be envisioned to take place when Sdc1 engages the heparin-binding domains of multivalent matrix ligands. SSTN appears to inhibit tumorigenesis and angiogenesis by displacing Sdc1 from the integrins and, thus, blocking their activation during this clustering event.
###end p 42
###begin title 43
MATERIALS AND METHODS
###end title 43
###begin title 44

###end title 44
###begin title 45
Materials.
###end title 45
###begin p 46
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib60">60</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib61">61</xref>
###xml 576 577 572 573 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 583 584 576 577 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 594 595 584 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 669 670 656 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 720 721 703 704 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 725 726 705 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 736 737 712 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 781 782 753 754 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 786 787 755 756 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 949 950 915 916 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1068 1069 1030 1031 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1073 1074 1032 1033 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 1277 1278 1232 1233 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1282 1283 1234 1235 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1374 1376 1326 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 35 40 <span type="species:ncbi:10090">mouse</span>
###xml 86 89 <span type="species:ncbi:10116">rat</span>
###xml 114 120 <span type="species:ncbi:9986">Rabbit</span>
###xml 246 251 <span type="species:ncbi:10090">Mouse</span>
###xml 933 939 <span type="species:ncbi:9986">rabbit</span>
###xml 1057 1062 <span type="species:ncbi:10090">Mouse</span>
###xml 1379 1382 <span type="species:ncbi:10116">Rat</span>
###xml 1429 1434 <span type="species:ncbi:10090">mouse</span>
###xml 1489 1494 <span type="species:ncbi:10090">Mouse</span>
Sdc1-specific antibodies used were mouse mAbs B-B4 and B-A38 (hSdc1; AbD Serotec) and rat mAb 281.2 (mSdc1) (60). Rabbit polyclonal antibodies against recombinant mS1ED were affinity purified as previously described (20) and used to detect SSTN. Mouse mAb 3G10, which specifically recognizes terminal unsaturated uronic acid residues that remain on the core protein after treatment with heparin lyases (61), was used for simultaneous detection of mSdc1 and hSdc1 on Western blots. Integrin antibodies include the polyclonal antibodies AB1923, AB1932, and AB1926 (against alphav, beta3, and beta5, respectively; Millipore) and mAb N29 (used for Western blotting for beta1; Millipore); blocking mAbs P1F6 and M9 (for alphavbeta5 and alphav, respectively; Millipore), LM609 (for alphavbeta3; courtesy of D. Cheresh, University of California, San Diego, La Jolla, CA, and the Scripps Research Institute, La Jolla, CA); and "Fire & Ice" (rabbit anti-beta3; courtesy of P. Newman, Blood Research Institute, Blood Center of Southeastern Wisconsin, Milwaukee, WI). Mouse alphavbeta5 ALULA function-blocking mAb was provided courtesy of D. Sheppard (University of California, San Francisco, San Francisco, CA). WOW-1, a ligand-mimetic Fab that serves as an "activation sensor" for alphavbeta3, was provided courtesy of S. Shattil (University of California, San Diego, La Jolla, CA) (30). Rat mAbs MEC 13.3 (BD) or 390 (Millipore) against mouse CD31/PECAM-1 were used to identify endothelial cells. Mouse mAb D33 (Dako) against desmin was used to identify pericytes.
###end p 46
###begin p 47
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">62</xref>
###xml 236 238 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib63">63</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 163 167 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 193 197 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 219 234 <span type="species:ncbi:10090">transgenic mice</span>
Mouse mammary tumors were provided by C. Alexander (University of Wisconsin-Madison, Madison, WI); tumors were from mice overexpressing Wnt-1 under control of the MMTV-LTR (31, 62) or from FVB MMTV-DeltaN89beta-catenin transgenic mice (63). Tumors were embedded in optimum cutting temperature (OCT) compound (VWR) and frozen sections were prepared for staining.
###end p 47
###begin p 48
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
The SSTN peptides (80-90% pure) were purchased from GenScript Corporation. They are based on the mSdc1 sequence. Recombinant mS1ED fusion protein was prepared as previously described (20).
###end p 48
###begin p 49
###xml 52 54 52 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib64">64</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib65">65</xref>
###xml 34 37 <span type="species:ncbi:10116">rat</span>
###xml 189 194 <span type="species:ncbi:9606">human</span>
Type-I collagen was purified from rat tail tendons (64), solubilized in 0.1 M acetic acid, and dialyzed against 0.1x DMEM (no serum) at pH 4 to remove the acetic acid. VN was purified from human plasma using a previously described method (65).
###end p 49
###begin title 50
Cell culture.
###end title 50
###begin p 51
###xml 63 64 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 222 223 216 217 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 510 512 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib66">66</xref>
###xml 691 693 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">67</xref>
###xml 843 844 833 834 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 867 868 857 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 515 519 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 750 755 <span type="species:ncbi:9606">Human</span>
###xml 948 954 <span type="species:ncbi:9913">bovine</span>
All cell lines were cultured at 37degreesC in 92.5% air/7.5% CO2. MDA-MB-231 human mammary carcinoma cells and MAECs were grown in DMEM (Thermo Fisher Scientific) supplemented with 10% FCS (Thermo Fisher Scientific), 4 mM l-glutamine (Sigma-Aldrich), and 100 U/ml penicillin and 100 microg/ml streptomycin (Invitrogen). MAECs and HAECs were provided by R. Auerbach (University of Wisconsin-Madison, Madison, WI). These are spontaneously immortalized cell lines identified as endothelial by phenotypic markers (66). SV40-T immortalized HMEC-1s were developed and provided by E.W. Ades and F.J. Candal (Center for Disease Control, Atlanta, GA) and T.J. Lawley (Emory University, Atlanta, GA) (67). HUVECs were obtained from Cambrex Life Sciences Corp. Human endothelial cells were cultured in MCDB-131 (Invitrogen) medium supplemented with 5 mM l-glutamine, 20 mM NaHCO3 (Sigma-Aldrich), 10 ng/ml epidermal growth factor, 1 microg/ml hydrocortisone, bovine brain extract with heparin and antibiotics (SingleQuot kit; Cambrex Life Sciences Corp.), and 15% FBS (Gemini Bio-Products).
###end p 51
###begin title 52
Cell attachment and spreading assay.
###end title 52
###begin p 53
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 160 168 160 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Silencer</italic>
Cell attachment and spreading assays on Sdc1-specific antibody or VN and silencing of Sdc1 expression by siRNA were conducted as previously described (19, 20). Silencer control siRNAs (Applera Corporation) were use for control siRNA transfections. Images were acquired using an objective (PlanFluor 10x [0.5 NA], PlanApo 20x [0.75 NA], or PlanApo 63x [1.4 NA]; Nikon) on a microscope (Microphot-FX; Nikon) equipped with a cooled charge-coupled device camera system (Image-Point; Nikon).
###end p 53
###begin title 54
Construction of mSdc1 mutant.
###end title 54
###begin p 55
###xml 9 20 9 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;67-121</sup>
The mSdc1Delta67-121 mutant was constructed by digesting full-length mSdc1 cDNA (pcDNA3; provided by R. Sanderson, University of Alabama at Birmingham, Birmingham, AL) with BmgBI and BstEII. The BstEII overhang was then filled in using the Klenow DNA polymerase fragment (Promega) and the vector then blunt-end ligated using T4 DNA ligase (New England Biolabs, Inc.). The mutant was transfected into MDA-MB-231 cells using LipofectAMINE PLUS (Invitrogen) and 10 microg of plasmid, in accordance with the manufacturer's instructions. A stable population (100-300 colonies) was selected in 1.5 mg/ml G418 (EMD) and comparatively sorted against cells expressing full-length mSdc1 for equal expression levels by flow cytometry using mAb 281.2 under sterile conditions on a triple-laser FACSVantage SE equipped with a FACSDiva digital electronics analyzer (BD).
###end p 55
###begin title 56
Flow cytometry.
###end title 56
###begin p 57
###xml 417 418 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 728 729 716 717 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 733 734 718 719 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1037 1038 1018 1019 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1580 1586 1541 1547 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 1962 1963 1915 1916 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1967 1968 1917 1918 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1143 1147 <span type="species:ncbi:9925">goat</span>
###xml 1153 1158 <span type="species:ncbi:10090">mouse</span>
###xml 1379 1383 <span type="species:ncbi:9925">goat</span>
###xml 1389 1394 <span type="species:ncbi:10090">mouse</span>
###xml 1804 1808 <span type="species:ncbi:9925">goat</span>
###xml 1814 1819 <span type="species:ncbi:10090">mouse</span>
Cells were scanned at the University of Wisconsin Comprehensive Cancer Center Flow Cytometry Facility using a benchtop cytometer (FACSCalibur; BD Biosciences). For cell-surface staining of Sdc1 and/or integrins, cells were lifted in Tris-buffered saline (TBS) containing 5mM EDTA (TES), washed in HEPES-buffered DMEM (Hb-DME) containing 10% serum, incubated for 1 h on ice with 1 microg of primary antibody per 5 x 105 cells, washed, and counterstained with Alexa Fluor 488-conjugated secondary antibodies (Invitrogen). Cell scatter and propidium iodide (1 microg per sample; Sigma-Aldrich) staining profiles were used to gate live, single-cell events for data analysis. For WOW1 Fab staining (i.e., detection of activated alphavbeta3 integrin), HUVECs were lifted in TES and washed in serum-free medium (Hb-DME containing 0.1% heat-denatured BSA [hdBSA]); this medium was used for all washes and incubations that follow unless otherwise specified. To cluster Sdc1, suspended cells were incubated with 1 microg/ml of mAb B-A38 per 5 x 105 cells (or mIgG1 as an isotype control) for 15 min at 37degreesC, washed, and incubated with 5 microg/ml goat anti-mouse IgG secondary antibody (Jackson ImmunoResearch Laboratories) for an additional 15 min. Cells were washed and blocked for 15 min in serum-free medium containing 1% hdBSA and a 1:100 dilution of monovalent Fab fragment of goat anti-mouse IgG. Cells were washed with a stoichiometric excess of serum-free medium and incubated with WOW-1 Fab (1:4 dilution) for 30 min at 37degreesC in the presence or absence of 1 microM SSTN82-130. Cells were washed with serum-free medium, fixed in 4% paraformaldehyde (PFA) for 30 min, and quenched in 0.1 M glycine (in PBS) for 15 min. Cells were then counterstained with 10 microg/ml Alexa Fluor 488-conjugated goat anti-mouse IgG secondary antibody (Invitrogen) before scanning. Mean fluorescent intensity of triplicate samples was used as a measure of activated alphavbeta3 integrin.
###end p 57
###begin title 58
Immunoprecipitations.
###end title 58
###begin p 59
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 392 393 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 1159 1160 1119 1120 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1190 1192 1150 1152 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 1617 1618 1567 1568 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1622 1623 1569 1570 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1632 1633 1575 1576 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1637 1638 1577 1578 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 1708 1714 1648 1654 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92-119</sub>
###xml 1737 1743 1677 1683 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">94-119</sub>
###xml 2127 2128 2057 2058 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 2132 2133 2059 2060 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 2504 2506 2431 2433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib68">68</xref>
###xml 2695 2696 2615 2616 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 2736 2737 2653 2654 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 2793 2794 2702 2703 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 567 570 <span type="species:ncbi:10116">rat</span>
###xml 591 596 <span type="species:ncbi:10090">mouse</span>
###xml 2679 2685 <span type="species:ncbi:9986">rabbit</span>
###xml 2709 2715 <span type="species:ncbi:9986">rabbit</span>
###xml 2771 2776 <span type="species:ncbi:10090">mouse</span>
###xml 2782 2787 <span type="species:ncbi:9606">human</span>
###xml 2933 2938 <span type="species:ncbi:10090">mouse</span>
mSdc1 and hSdc1 were immunoprecipitated using mAbs 281.2 and B-B4, respectively. 3-5 x 106 cells per milliliter were washed and lysed in buffer containing 50 mM HEPES (pH 7.4), 150 mM NaCl, 10 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, and a 1:100 dilution of protease inhibitor cocktail set III (EMD) for 20 min on ice. Insoluble cell debris was removed by centrifugation at 20,000 g for 15 min at 4degreesC. Cell lysates (2-mg input determined by BCA assay per reaction; Thermo Fisher Scientific) were precleared using 50 microg/ml of isotype-matched IgG (rat IgG2A for 281.2 and mouse IgG1 for B-B4) and 100 microl of GammaBind Sepharose (50:50 bead/lysis buffer slurry; GE Healthcare). Precleared lysates were incubated at 4degreesC overnight with 10 microg/ml of anti-syndecan antibody. For competition experiments, 30 microM GST (negative control), 30 microM GST-S1ED, or 3 microM SSTN was added to the precleared lysates in conjunction with anti-Sdc1 antibody. Immune complexes were precipitated with GammaBind Sepharose, pelleted, washed, and incubated in 50 microl of heparitinase buffer (50 mM Hepes, 50 mM NaOAc, 150 mM NaCl, and 5 mM CaCl2 [pH 6.5]) containing 2.4 x 10-3 IU/ml heparitinase (IBEX Technologies, Inc.) and 0.1 conventional U/ml of chondroitin ABC lysase (ICN Biochemicals) for 4 h at 37degreesC (with fresh enzymes added after 2 h) to remove glycosaminoglycan side chains from the immunoprecipitated syndecan. For precipitations using purified components, GST or GST-S1ED protein was immobilized to glutathione agarose beads (GE Healthcare) and incubated with either purified alphavbeta3 or alphavbeta5 integrin (U.S. Biological) in the presence of either competitive SSTN92-119 or noncompetitive SSTN94-119 peptide in sterile PBS containing the protease inhibitor cocktail for 4 h at 4degreesC. The samples were pelleted and washed in sterile PBS. In biotin label transfer assays, SSTN "bait" (active peptide 92-119 or inactive peptide 94-119) was labeled with Sulfo-SBED Biotin (Thermo Fisher Scientific) in accordance with the manufacturer's instructions and incubated with purified alphavbeta3 integrin "prey" protein in solution. The SBED conjugate was photoactivated with UV light (365 nm at 5 cm for 15 min) to cross-link the bait-prey complexes. After reversal of the cross-links with dithiothreitol, biotin-labeled prey protein was captured using monomeric avidin agarose beads (Thermo Fisher Scientific). All samples were extracted in Laemmli sample buffer (68) and resolved by electrophoresis on a 7.5% Laemmli gel, transferred to ImmobilonP, and probed with alkaline phosphatase (AP)-conjugated streptavidin alone, or 10 microg/ml rabbit anti-beta3 Fire & Ice, rabbit polyclonal anti-beta5 integrin (1:1,000), 10 microg/ml mouse anti-human alphav mAb 3F12 (courtesy of S. Blystone, State University of New York Upstate Medical University, Syracuse, NY), or 1 microg/ml polyclonal anti-mouse S1ED or mAb B-A38 antibody followed by an AP-conjugated secondary. Visualization of immunoreactive bands was performed using ECF reagent (GE Healthcare) and scanned on a Storm PhosphoImager (GE Healthcare).
###end p 59
###begin title 60
Aortic ring outgrowth assay.
###end title 60
###begin p 61
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 113 118 <span type="species:ncbi:10090">Mouse</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 378 383 <span type="species:ncbi:10090">mouse</span>
All animal experiments were approved by the University of Wisconsin Institutional Animal Care and Use Committee. Mouse aortic ring outgrowth assays were conducted as in Masson et al. (33). The thoracic aortae from female BALB/c mice were cut into 1-mm segments and placed in 1.6-mg/ml collagen gels containing MCDB-131 endothelial cell growth medium (Invitrogen) and fresh 2.5% mouse serum, 100 U/ml penicillin, and 100 microg/ml streptomycin. Media containing 30 ng/ml FGF-2 (PeproTech) or 50 ng/ml VEGF (PeproTech) and recombinant mS1ED or SSTN peptide was changed every 2 d for the duration of the experiment (7 d). Total vessel outgrowth was summed for each ring using Metamorph software (version 6.1; MDS Analytical Technologies). Immunofluorescent images were acquired using a PlanApo 20x (0.75 NA) objective and a camera (CoolSnap ES; Roper Scientific) on a microscopy system (Eclipse TE2000U; Nikon). Digital images were acquired using a dissecting microscope (SMZ1500; Nikon) and a digital camera (CoolPix E5000; Nikon).
###end p 61
###begin title 62
Corneal angiogenesis assay.
###end title 62
###begin p 63
###xml 785 786 759 760 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
###xml 955 960 <span type="species:ncbi:10090">mouse</span>
###xml 1124 1129 <span type="species:ncbi:10090">mouse</span>
For corneal angiogenesis, pellets were created using 3 vol Poly-HEMA (Sigma-Aldrich) in 95% ethanol, and 1 vol each of sucralfate (100 microg/ml in PBS; Sigma-Aldrich), FGF-2 (3.2 mg/ml in PBS; PeproTech), and PBS. The solution was rapidly mixed, and 0.5-microl drops were allowed to dry for 1 h at 4degreesC before being cut into four equal 0.125-microl sections for implantation into corneal pockets created in anesthetized mice using a 1.5-mm microdissecting knife (Roboz Surgical Instrument Company, Inc.). Osmotic pumps (model 2004; Alzet Osmotic Pumps) delivering 1 microl/h containing PBS or PBS with a range of SSTN concentrations from 0-100 microM, or PBS containing 22.7 mM cRGDfV or cRADfV peptide (Enzo Life Sciences, Inc.), reconstituted in a 50:50 DMSO/double-distilled H2O solution, were implanted immediately after pellet implantation. After 7 d, 0.1 ml FITC-dextran (2,000,000 mol wt; Sigma-Aldrich) was retroorbitally injected into each mouse before sacrifice, and corneas were removed and fixed in 4% PFA for imaging. Total vessel outgrowth from the limbic vessel at the cornea margin was summed for each mouse using Metamorph software. Immunofluorescent images were acquired using a PlanFluor 4x (0.45 NA) objective and a CoolSnap ES camera on an Eclipse TE2000U microscopy system. Digital images were acquired using a SMZ1500 dissecting microscope and a CoolPix E5000 digital camera.
###end p 63
###begin title 64
Subcutaneous tumors.
###end title 64
###begin p 65
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 456 462 452 458 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">82-130</sub>
###xml 46 51 <span type="species:ncbi:9606">human</span>
###xml 179 188 <span type="species:ncbi:10090">nude mice</span>
###xml 626 630 <span type="species:ncbi:10090">mice</span>
Under asceptic conditions, 5 x 106 MDA-MB-231 human mammary carcinoma cells (0.2 ml vol) were injected subcutaneously in the right rear flank of 6-8-wk-old female, athymic BALB/c nude mice (Taconic) using a 3-ml sterile syringe and a 26-gauge needle. Palpable tumors were allowed to form for 1 wk after injection, at which time each animal was surgically implanted with an Alzet osmotic pump (0.25 microl/h) containing either PBS (control) or PBS plus SSTN82-130 peptide (either 120 or 400 microM). Tumor growth was monitored for an additional 4 wk by weekly examination and caliper measurements. At 5 wk after injection, the mice were humanely sacrificed and tumors/serum were harvested.
###end p 65
###begin p 66
###xml 132 133 128 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 284 288 <span type="species:ncbi:9925">goat</span>
###xml 323 326 <span type="species:ncbi:10116">rat</span>
###xml 332 337 <span type="species:ncbi:10090">mouse</span>
###xml 401 406 <span type="species:ncbi:10090">mouse</span>
###xml 470 474 <span type="species:ncbi:9925">goat</span>
###xml 480 483 <span type="species:ncbi:10116">rat</span>
###xml 484 489 <span type="species:ncbi:10090">mouse</span>
###xml 792 796 <span type="species:ncbi:10090">mice</span>
5-8-microm serial sections cut from frozen, OCT-embedded tumors were periodate-lysine-paraformaldehyde fixed, quenched in 0.05% NaBH4 followed by 0.1M glycine, and permeabilized/blocked in IHC buffer (0.02% NaN3, 0.1% BSA, 0.2% Triton X-100, and 0.05% Tween 20 in PBS) containing 10% goat serum. Sections were stained with rat anti-mouse PECAM-1/CD31 mAb MEC 13.3 (1:25 dilution in IHC buffer) and/or mouse anti-desmin (used neat) followed by Alexa Fluor 488-conjugated goat anti-rat/mouse secondary antibody. Images were acquired using a PlanFluor 40x objective (1.3 NA; Nikon) and a CoolSnap ES camera on an Eclipse TE2000U microscopy system. Mean vessel length and PECAM-1 staining intensity were calculated across six representative fields for each cohort (i.e., control vs. SSTN-treated mice) using Metamorph software.
###end p 66
###begin title 67
Dot blots.
###end title 67
###begin p 68
###xml 75 81 <span type="species:ncbi:9986">rabbit</span>
###xml 123 128 <span type="species:ncbi:10090">mouse</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 636 642 <span type="species:ncbi:9793">donkey</span>
###xml 648 654 <span type="species:ncbi:9986">rabbit</span>
###xml 975 979 <span type="species:ncbi:10090">mice</span>
SSTN serum levels were calculated by dot blotting using affinity-purified, rabbit polyclonal anti-S1ED antibody. In brief, mouse serum collected from SSTN-treated and control mice was pooled and heated at 65degreesC for 20-30 min (to inactivate endogenous AP activity), and 200 microl was spotted in triplicate on 0.2 microm nitrocellulose (Bio-Rad Laboratories) using a vacuum (Minifold Dot-Blot System; Schleicher & Schuell). After washing, the membrane was fixed in 0.25% glutaraldehyde for 30 min, blocked in TBS containing 6% BSA for 2 h at 4degreesC, and then probed using 1 microg/ml anti-S1ED antibody followed by AP-conjugated donkey anti-rabbit secondary antibody (1:5,000 dilution). Immunoreactive wells were visualized using ECF reagent and scanned on a Storm PhosphoImager. SSTN levels were calculated using Image Quant software (GE Healthcare) by comparison against a standard curve (i.e., 0-18 microM SSTN-spiked, heat-inactivated serum collected from control mice) spotted on the same blot.
###end p 68
###begin title 69
Statistical analyses.
###end title 69
###begin p 70
###xml 50 51 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Statistical analyses using a two-tailed Student's t test were performed using Prism software (version 5; GraphPad Software, Inc.). Data that satisfy confidence levels of P < 0.05 or 0.01 are noted. Data are presented as means +/- SEM, unless otherwise noted.
###end p 70
###begin p 71
Drs. D. Cheresh and S. Shattil, C. Alexander and R. Auerbach, P. Newman, D. Sheppard, S. Blystone, and R. Sanderson are thanked for generously providing cells, tissues, and/or reagents used in this work. G. Thomas is thanked for technical assistance, and Dr. R. Sanderson is thanked for critically reading the manuscript.
###end p 71
###begin p 72
This work was supported by funds to A.C. Rapraeger from the National Institutes of Health (grants R01-CA109010 and CA118839) and the American Heart Association (grant AHA0655734Z), and the Robert Draper Technology Innovation Fund of the University of Wisconsin. D.M. Beauvais is supported by a Susan G. Komen Foundation postdoctoral fellowship.
###end p 72
###begin p 73
The authors have no conflicting financial interests.
###end p 73
###begin article-title 74
Angiogenesis.
###end article-title 74
###begin article-title 75
Cell-matrix adhesion in vascular development.
###end article-title 75
###begin article-title 76
Apoptotic cues from the extracellular matrix: regulators of angiogenesis.
###end article-title 76
###begin article-title 77
Definition of two angiogenic pathways by distinct alpha(v) integrins.
###end article-title 77
###begin article-title 78
Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins.
###end article-title 78
###begin article-title 79
Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo.
###end article-title 79
###begin article-title 80
Molecular pathway for cancer metastasis to bone.
###end article-title 80
###begin article-title 81
###xml 80 85 <span type="species:ncbi:9606">human</span>
Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells.
###end article-title 81
###begin article-title 82
Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells.
###end article-title 82
###begin article-title 83
Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.
###end article-title 83
###begin article-title 84
Requirement of vascular integrin alpha v beta 3 for angiogenesis.
###end article-title 84
###begin article-title 85
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.
###end article-title 85
###begin article-title 86
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.
###end article-title 86
###begin article-title 87
Inhibition of the alpha-V integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo.
###end article-title 87
###begin article-title 88
Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
###end article-title 88
###begin article-title 89
###xml 113 117 <span type="species:ncbi:10090">mice</span>
Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
###end article-title 89
###begin article-title 90
###xml 86 91 <span type="species:ncbi:9606">human</span>
Syndecan-1-mediated cell spreading requires signaling by alpha(v)beta(3) integrins in human breast carcinoma cells.
###end article-title 90
###begin article-title 91
Syndecans in tumor cell adhesion and signaling.
###end article-title 91
###begin article-title 92
Syndecan-1 regulates alpha(v)beta(5) integrin activity in B82L fibroblasts.
###end article-title 92
###begin article-title 93
###xml 41 42 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 46 47 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 69 74 <span type="species:ncbi:9606">human</span>
The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells.
###end article-title 93
###begin article-title 94
Functions of cell surface heparan sulfate proteoglycans.
###end article-title 94
###begin article-title 95
Syndecans in wound healing, inflammation and vascular biology.
###end article-title 95
###begin article-title 96
Syndecans: transmembrane modulators of adhesion and matrix assembly.
###end article-title 96
###begin article-title 97
Characterization of the high affinity cell-binding domain in the cell surface proteoglycan syndecan-4.
###end article-title 97
###begin article-title 98
Identification of an adhesion site within the syndecan-4 extracellular protein domain.
###end article-title 98
###begin article-title 99
A conserved NXIP motif is required for cell adhesion properties of the syndecan-4 ectodomain.
###end article-title 99
###begin article-title 100
Syndecans promote integrin-mediated adhesion of mesenchymal cells in two distinct pathways.
###end article-title 100
###begin article-title 101
New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells.
###end article-title 101
###begin article-title 102
Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells.
###end article-title 102
###begin article-title 103
Mechanisms and consequences of affinity modulation of integrin alpha(v)beta(3) detected with a novel patch-engineered monovalent ligand.
###end article-title 103
###begin article-title 104
###xml 32 47 <span type="species:ncbi:10090">transgenic mice</span>
###xml 132 136 <span type="species:ncbi:10090">mice</span>
Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice.
###end article-title 104
###begin article-title 105
DeltaN89beta-catenin induces precocious development, differentiation, and neoplasia in mammary gland.
###end article-title 105
###begin article-title 106
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse aortic ring assay: a new approach of the molecular genetics of angiogenesis.
###end article-title 106
###begin article-title 107
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
A model of angiogenesis in the mouse cornea.
###end article-title 107
###begin article-title 108
Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival.
###end article-title 108
###begin article-title 109
Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature.
###end article-title 109
###begin article-title 110
Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.
###end article-title 110
###begin article-title 111
###xml 98 101 <span type="species:ncbi:10116">rat</span>
Differential expression and distribution of syndecan-1 and -2 in periodontal wound healing of the rat.
###end article-title 111
###begin article-title 112
Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin.
###end article-title 112
###begin article-title 113
Suppression of syndecan-1 expression in endothelial cells by tumor necrosis factor-alpha.
###end article-title 113
###begin article-title 114
Induced expression of syndecan in healing wounds.
###end article-title 114
###begin article-title 115
Macrophage-dependent regulation of syndecan gene expression.
###end article-title 115
###begin article-title 116
###xml 28 34 <span type="species:ncbi:9986">rabbit</span>
Expression of syndecan-1 in rabbit neointima following de-endothelialization by a balloon catheter.
###end article-title 116
###begin article-title 117
Syndecan-1 up-regulated by ephrinB2/EphB4 plays dual roles in inflammatory angiogenesis.
###end article-title 117
###begin article-title 118
Induction of the angiogenic phenotype by Hox D3.
###end article-title 118
###begin article-title 119
The homeobox transcription factor Hox D3 promotes integrin alpha5beta1 expression and function during angiogenesis.
###end article-title 119
###begin article-title 120
Homeobox B3 promotes capillary morphogenesis and angiogenesis.
###end article-title 120
###begin article-title 121
Integrin-associated proteins.
###end article-title 121
###begin article-title 122
Cholesterol-independent interactions with CD47 enhance alpha(v)beta(3) avidity.
###end article-title 122
###begin article-title 123
Thrombospondin-bound integrin-associated protein (CD47) physically and functionally modifies integrin alpha(IIb)beta(3) by its extracellular domain.
###end article-title 123
###begin article-title 124
Activation of alpha(v)beta(3)-vitronectin binding is a multistage process in which increases in bond strength are dependent on Y747 and Y759 in the cytoplasmic domain of beta(3).
###end article-title 124
###begin article-title 125
Probing chemical and conformational differences in the resting and active conformers of platelet integrin alpha(IIb)beta(3).
###end article-title 125
###begin article-title 126
Ligands "activate" integrin alpha(IIb)beta(3) (platelet GPIIb-IIIa).
###end article-title 126
###begin article-title 127
Monoclonal antibodies to ligand-occupied conformers of integrin alpha(IIb)beta(3) (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function.
###end article-title 127
###begin article-title 128
Integrin activation: the link between ligand binding and signal transduction.
###end article-title 128
###begin article-title 129
Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling.
###end article-title 129
###begin article-title 130
Talin binding to integrin beta tails: a final common step in integrin activation.
###end article-title 130
###begin article-title 131
Structural basis of integrin activation by talin.
###end article-title 131
###begin article-title 132
Activation of integrin alpha(IIb)beta(3) by modulation of transmembrane helix associations.
###end article-title 132
###begin article-title 133
###xml 35 40 <span type="species:ncbi:10090">mouse</span>
Heparan sulfate proteoglycans from mouse mammary epithelial cells: localization on the cell surface with a monoclonal antibody.
###end article-title 133
###begin article-title 134
Molecular cloning of amphiglycan, a novel integral membrane heparan sulfate proteoglycan expressed by epithelial and fibroblastic cells.
###end article-title 134
###begin article-title 135
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice.
###end article-title 135
###begin article-title 136
Mammary gland development requires syndecan-1 to create a beta-catenin/TCF-responsive mammary epithelial subpopulation.
###end article-title 136
###begin article-title 137
###xml 46 49 <span type="species:ncbi:10116">rat</span>
Preparation of intact monomeric collagen from rat tail tendon and skin and the structure of the nonhelical ends in solution.
###end article-title 137
###begin article-title 138
###xml 39 44 <span type="species:ncbi:9606">human</span>
Novel purification of vitronectin from human plasma by heparin affinity chromatography.
###end article-title 138
###begin article-title 139
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
Heterogeneity of mouse vascular endothelium. In vitro studies of lymphatic, large blood vessel and microvascular endothelial cells.
###end article-title 139
###begin article-title 140
###xml 41 46 <span type="species:ncbi:9606">human</span>
HMEC-1: establishment of an immortalized human microvascular endothelial cell line.
###end article-title 140
###begin article-title 141
###xml 67 83 <span type="species:ncbi:10665">bacteriophage T4</span>
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
###end article-title 141
###begin p 142
###xml 106 111 <span type="species:ncbi:9606">human</span>
###xml 145 150 <span type="species:ncbi:9606">human</span>
###xml 218 223 <span type="species:ncbi:9606">human</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 282 287 <span type="species:ncbi:10090">mouse</span>
###xml 320 325 <span type="species:ncbi:10090">mouse</span>
Abbreviations used: FGF, fibroblast growth factor; FN, fibronectin; GST, glutathione S-transferase; HAEC, human aortic endothelial cell; HMEC-1, human dermal microvascular endothelial cell; HS, heparan sulfate; hSdc1, human Sdc1; HUVEC, human umbilical vein endothelial cell; MAEC, mouse aortic endothelial cell; mSdc1, mouse Sdc1; OCT, optimum cutting temperature; PECAM-1, platelet-endothelial cell adhesion molecule-1; Poly-HEMA, poly(2-hydroxyethyl methacrylate); siRNA, small interfering RNA; Sdc1, syndecan-1; S1ED, Sdc1 extracellular domain; SSTN, synstatin; VEGF, vascular endothelial growth factor; VN, vitronectin.
###end p 142

